Monte Rosa CMO sells 6,000 shares after option exercise
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an exercise-and-sell transaction in company stock.
Rhea-AI Filing Summary
Monte Rosa Therapeutics Chief Medical Officer Filip Janku reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 6,000 shares of Common Stock at $7.56 per share and on the same date sold 6,000 shares at $22.95 per share in an open-market transaction.
After these transactions, Janku directly holds 59,992 shares of Common Stock and retains 60,000 stock options that remain outstanding and fully vested. The company notes these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 4, 2026, indicating they were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 6,000 shares ($92K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Janku Filip
Role
Chief Medical Officer
Sold
6,000 shs ($138K)
Approx. gross sale proceeds
$138K
Approx. exercise cost
$45K
Approx. pre-tax spread
$92K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 6,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,000 | $7.56 | $45K |
| Sale | Common Stock | 6,000 | $22.95 | $138K |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 contracts (Direct);
Common Stock — 59,992 shares (Direct)
Footnotes (2)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.
- F2. The shares underlying this option are fully vested and exercisable.
Key Figures
Shares sold: 6,000 shares
Sale price: $22.95 per share
Options exercised: 6,000 shares
+5 more
8 metrics
Shares sold
6,000 shares
Open-market sale of Common Stock
Sale price
$22.95 per share
Price received for 6,000 Common shares
Options exercised
6,000 shares
Stock option exercise into Common Stock
Option strike price
$7.56 per share
Conversion or exercise price of stock option
Shares held after
59,992 shares
Direct Common Stock holdings post-transaction
Options remaining
60,000 options
Fully vested stock options outstanding after exercise
Rule 10b5-1 plan adoption date
March 4, 2026
Date stated for trading plan governing transactions
Option expiration
2032-10-03
Expiration date of the stock option grant
Key Terms
Rule 10b5-1 trading plan, Stock Option (Right to Buy), open-market sale, derivative exercise/conversion, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 6,000 underlying shares of Common Stock."
open-market sale financial
"transaction_action: open-market sale of 6,000 shares of Common Stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion of stock options into Common Stock."
Chief Medical Officer other
"Reporting person Janku Filip serves as Chief Medical Officer of Monte Rosa Therapeutics, Inc."
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Monte Rosa Therapeutics (GLUE) report for Filip Janku?
Monte Rosa Therapeutics reported that Chief Medical Officer Filip Janku exercised and sold 6,000 shares. He exercised options for 6,000 shares and sold 6,000 shares of Common Stock in an open-market transaction on the same date, reflecting an exercise-and-sell pattern.
What stock option position does Filip Janku retain in Monte Rosa Therapeutics (GLUE)?
Following the exercise, Filip Janku retains 60,000 stock options in Monte Rosa Therapeutics. These options are fully vested and exercisable, with a conversion or exercise price of $7.56 per share and an expiration date in 2032, indicating a remaining long-term equity incentive.
AI-generated analysis. How Rhea-AI works. Not financial advice.
